JPWO2019155286A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019155286A5 JPWO2019155286A5 JP2020542380A JP2020542380A JPWO2019155286A5 JP WO2019155286 A5 JPWO2019155286 A5 JP WO2019155286A5 JP 2020542380 A JP2020542380 A JP 2020542380A JP 2020542380 A JP2020542380 A JP 2020542380A JP WO2019155286 A5 JPWO2019155286 A5 JP WO2019155286A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cells
- seq
- target cell
- cell antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 55
- 102000005962 receptors Human genes 0.000 claims 43
- 108020003175 receptors Proteins 0.000 claims 43
- 239000000427 antigen Substances 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 210000000822 natural killer cell Anatomy 0.000 claims 30
- 239000000853 adhesive Substances 0.000 claims 24
- 230000001070 adhesive effect Effects 0.000 claims 24
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 10
- 230000001464 adherent effect Effects 0.000 claims 9
- 102000019997 adhesion receptor Human genes 0.000 claims 9
- 108010013985 adhesion receptor Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 8
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 4
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 4
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628797P | 2018-02-09 | 2018-02-09 | |
| US62/628,797 | 2018-02-09 | ||
| US201862736965P | 2018-09-26 | 2018-09-26 | |
| US62/736,965 | 2018-09-26 | ||
| PCT/IB2019/000141 WO2019155286A2 (en) | 2018-02-09 | 2019-02-07 | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512614A JP2021512614A (ja) | 2021-05-20 |
| JP2021512614A5 JP2021512614A5 (https=) | 2022-02-09 |
| JPWO2019155286A5 true JPWO2019155286A5 (https=) | 2022-02-09 |
Family
ID=67548047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542380A Pending JP2021512614A (ja) | 2018-02-09 | 2019-02-07 | ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210054409A1 (https=) |
| EP (1) | EP3749686A4 (https=) |
| JP (1) | JP2021512614A (https=) |
| CN (1) | CN111712516A (https=) |
| AU (1) | AU2019219452A1 (https=) |
| CA (1) | CA3089167A1 (https=) |
| SG (1) | SG11202007183PA (https=) |
| WO (1) | WO2019155286A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN110396131B (zh) * | 2019-08-23 | 2020-07-10 | 北京鼎成肽源生物技术有限公司 | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN115197326B (zh) * | 2022-06-27 | 2025-05-16 | 安徽医科大学第一附属医院 | 融合蛋白及其编码基因和重组载体以及它们的应用 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
| CN120098148B (zh) * | 2025-05-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞制备及抗纤维化的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2782333C (en) * | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) * | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3157958B1 (en) * | 2014-06-18 | 2020-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing nk-92 cells as cell therapeutic agents |
| WO2017027325A1 (en) * | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| SG11201810640RA (en) * | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| KR102660336B1 (ko) * | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
-
2019
- 2019-02-07 EP EP19750822.9A patent/EP3749686A4/en not_active Withdrawn
- 2019-02-07 US US16/967,888 patent/US20210054409A1/en not_active Abandoned
- 2019-02-07 CN CN201980011826.9A patent/CN111712516A/zh active Pending
- 2019-02-07 AU AU2019219452A patent/AU2019219452A1/en not_active Abandoned
- 2019-02-07 WO PCT/IB2019/000141 patent/WO2019155286A2/en not_active Ceased
- 2019-02-07 CA CA3089167A patent/CA3089167A1/en not_active Abandoned
- 2019-02-07 SG SG11202007183PA patent/SG11202007183PA/en unknown
- 2019-02-07 JP JP2020542380A patent/JP2021512614A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512614A5 (https=) | ||
| KR102952460B1 (ko) | Cd3 항체 및 그의 약제학적 용도 | |
| ES2289156T3 (es) | Molecula de anticuerpo anti-cd28 biespecifica. | |
| JP7029822B2 (ja) | 抗原特異的ｔ細胞及びその使用 | |
| AU2012277784B2 (en) | Antibodies against prostate-specific stem cell antigen and use thereof | |
| TW202535924A (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| KR102070016B1 (ko) | 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포 | |
| JPWO2019155286A5 (https=) | ||
| JP2020510407A (ja) | 抗ｐｄ−１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 | |
| KR102216225B1 (ko) | 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포 | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| Spillner et al. | Recombinant IgE antibody engineering to target EGFR | |
| CN113754775A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| Fan et al. | AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| KR20200019946A (ko) | 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용 | |
| CN116135884A (zh) | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| KR20230006823A (ko) | Her2를 표적화하는 항원 결합 구조체 및 이의 용도 | |
| CN110938146B (zh) | Tim-3单域抗体及其应用 | |
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| CN114763387B (zh) | 一种基于结构优化蛋白活性的三特异性抗体制备方法 | |
| CN105385694B (zh) | 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用 | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| Zhao et al. | Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells | |
| US12534518B2 (en) | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof |